Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
The FEBS Journal
|
October 17, 2017
Nonapoptotic functions of Fas/CD95 in the immune response
Jean-Philippe Guégan, Patrick Legembre
International Journal of Hepatology
|
November 8, 2012
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
Jean-Philippe Guégan, Christophe Frémin, Georges Baffet
Journal of Cellular Physiology
|
February 7, 2014
MEK1/2 overactivation can promote growth arrest by mediating ERK1/2-dependent phosphorylation of p70S6K
Jean-Philippe Guégan, Frédéric Ezan, Luc Gailhouste, et al.
Carcinogenesis
|
October 9, 2012
MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells
Jean-Philippe Guégan, Frédéric Ezan, Nathalie Théret, et al.
Iscience
|
December 17, 2021
CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism
Jean-Philippe Guégan, Justine Pollet, Christophe Ginestier, et al.
Seminars in Cancer Biology
|
June 10, 2019
CD95/Fas and metastatic disease: What does not kill you makes you stronger
Jean Philippe Guégan, Christophe Ginestier, Emmanuelle Charafe-Jauffret, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 19, 2019
Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction
Ha Thanh Nguyen, Jean-Philippe Guégan, Daniel Best, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 15, 2019
Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis
Ha Thanh Nguyen, Jean-Philippe Guégan, Amanda Poissonnier, et al.
Signal Transduction and Targeted Therapy
|
June 27, 2025
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab
Maud Toulmonde, Jean-Philippe Guégan, Mariella Spalato-Ceruso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2023
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer
Alban Bessede, Florent Peyraud, Benjamin Besse, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
The FEBS Journal
|
October 17, 2017
Nonapoptotic functions of Fas/CD95 in the immune response
Jean-Philippe Guégan, Patrick Legembre
International Journal of Hepatology
|
November 8, 2012
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
Jean-Philippe Guégan, Christophe Frémin, Georges Baffet
Journal of Cellular Physiology
|
February 7, 2014
MEK1/2 overactivation can promote growth arrest by mediating ERK1/2-dependent phosphorylation of p70S6K
Jean-Philippe Guégan, Frédéric Ezan, Luc Gailhouste, et al.
Carcinogenesis
|
October 9, 2012
MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells
Jean-Philippe Guégan, Frédéric Ezan, Nathalie Théret, et al.
Iscience
|
December 17, 2021
CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism
Jean-Philippe Guégan, Justine Pollet, Christophe Ginestier, et al.
Seminars in Cancer Biology
|
June 10, 2019
CD95/Fas and metastatic disease: What does not kill you makes you stronger
Jean Philippe Guégan, Christophe Ginestier, Emmanuelle Charafe-Jauffret, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 19, 2019
Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction
Ha Thanh Nguyen, Jean-Philippe Guégan, Daniel Best, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 15, 2019
Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis
Ha Thanh Nguyen, Jean-Philippe Guégan, Amanda Poissonnier, et al.
Signal Transduction and Targeted Therapy
|
June 27, 2025
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab
Maud Toulmonde, Jean-Philippe Guégan, Mariella Spalato-Ceruso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2023
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer
Alban Bessede, Florent Peyraud, Benjamin Besse, et al.
Page
of 3